Wilmer Cutler Pickering Hale and Dorr represented Telix Pharmaceuticals Limited in the transaction. Telix Pharmaceuticals Limited (ASX: TLX) (Telix), a biopharmaceutical company, announced its acquisition of...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Eliem Therapeutics on the deal, and Cooley advised Tenet Medicines. Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced that it had entered into...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Arbor Biotechnologies in the transaction. Arbor Biotechnologies announced a strategic partnership with 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT). As part of...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Voyager Therapeutics, Inc. in the transaction. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced a strategic collaboration and capsid license agreement with...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Voyager Therapeutics on the deal. Voyager Therapeutics announced that it entered into a strategic collaboration agreement with Neurocrine Biosciences...
You must be a Standard 1 Year member to access this content.
WilmerHale advised Voyager Therapeutics on the deal. Voyager Therapeutics, a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, announced it entered into...
You must be a Standard 1 Year member to access this content.
